Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ME-344 + topotecan
- Development stage
- Discontinued
- Lead developer
- MEI Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A **combination therapy** of ME-344, a mitochondrial inhibitor, and topotecan, a topoisomerase I inhibitor, studied primarily for solid tumors including **small cell lung cancer**, **ovarian cancer**, and **cervical cancer**. ME-344 disrupts mitochondrial function and induces cancer cell death, acting independently of caspase-mediated pathways and showing effectiveness against chemotherapy-resistant cancer stem cells in preclinical models. Topotecan inhibits DNA topoisomerase I, leading to DNA damage in S-phase cells. The combination was tested for synergistic antitumor effects but, while tolerable, did not demonstrate sufficient efficacy to warrant further study in unselected advanced ovarian, cervical, or small cell lung cancer populations[1][5][3][4].
- Other names
- ME-344 plus topotecanME344 plus topotecanME 344 plus topotecanME-344 and topotecanME344 and topotecanME 344 and topotecan
02
Targets
TOP1 (DNA Topoisomerase I)HMOX1 (Heme oxygenase 1)ND1 (Mitochondrial electron transport chain complex I)TUBB (Tubulin (alpha and beta subunits))Neuraminidase
Beyond the preview
Go deeper on ME-344 + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ME-344 + topotecan.